サンプル依頼リスト カート
  • English
  • Korean
デフォルト表紙
市場調査レポート
商品コード
1362917

がん生検の市場規模、シェア、動向分析レポート：タイプ別、用途別、製品別、地域別、セグメント別予測、2023年～2030年

Cancer Biopsy Market Size, Share & Trends Analysis Report By Type (Liquid Biopsy, Core Needle Biopsy), By Application (Breast Cancer, Lung Cancer), By Product (Kits & Consumables, Instruments), By Region, And Segment Forecasts, 2023 - 2030
出版日: | 発行: Grand View Research | ページ情報: 英文 140 Pages | 納期: 2～10営業日

● お客様のご希望に応じて、既存データの加工や未掲載情報（例：国別セグメント）の追加などの対応が可能です。　 詳細はお問い合わせください。

価格
価格表記: USDを日本円(税抜)に換算
本日の銀行送金レート: 1USD=156.53円
がん生検の市場規模、シェア、動向分析レポート：タイプ別、用途別、製品別、地域別、セグメント別予測、2023年～2030年
出版日: 2023年09月07日
発行: Grand View Research
ページ情報: 英文 140 Pages
納期: 2～10営業日
  • 全表示
  • 概要
  • 図表
  • 目次
概要

がん生検市場の成長と動向：

Grand View Research, Inc.の最新レポートによると、世界のがん生検市場規模は2030年までに516億1,000万米ドルに達し、CAGR 8.04％で拡大すると予測されています。

分子医学の進歩は、がんの分子特性解析のための新しい装置の創出を促進しました。その結果、リキッドバイオプシーの受容と承認の高まりが市場全体の成長の大きな原動力になると予測されています。

数多くの新興メーカーが、内視鏡ベースのがん生検を改善できる機器の開発に専念しています。例えば、2023年3月、スウェーデンのBiBBInstruments AB社は、EndoDrillというブランドでがん生検装置市場に確固たる地位を築いた。同社は、既存の生検器具に関連して、がん患者の迅速かつ正確な診断を可能にする生検器具を変更しました。さらに、コアニードルや軟性内視鏡生検に対応した生検器具を提供しています。このような新興国市場を開拓している企業は、がん生検器具のアクセシビリティを高めると予想されます。

腫瘍学に基づくゲノムデータ解析と個別化医療の分野は、リキッドバイオプシーの出現によって有利な展望を示すと予想されます。規制機関は、リキッドバイオプシーがもたらす大きな可能性により、これらの製品の商業化を積極的に支援し、臨床現場での利用を促進しています。リキッドバイオプシーは、様々な体液を通してがんの検出を容易にし、この技術の進歩により、診断目的のがん生体物質を得るための魅力的な非侵襲的アプローチとなっています。

リキッドバイオプシー分野は、バイオ医薬品製造やゲノムデータ解析に携わる企業の多額の投資や戦略的努力によって、今後数年間で急速に拡大すると予測されています。新興企業は、QIAGEN Bioinformatics、Fabric Genomics、Agilent Technologies、SOPHiA Geneticsのような既存の業界参加企業とパートナーシップを結ぶことに強い傾向を示しています。このような共同研究の動向は、市場全体の成長をさらに押し上げると予想されます。

がん生検市場レポートハイライト

  • 2022年、キットと消耗品が製品別で最大の市場シェアを占め、この優位性は予測期間を通じて持続すると予測されます。キットおよび消耗品の採用が増加した背景には、腫瘍生検からリキッド生検への顕著な移行があります。
  • 組織生検は依然として生検プロセスの基本であり、さまざまな診断用途で広く利用されています。さらに、腫瘍生検は主に個人レベルの診断と進行中の腫瘍学的治療の有効性のモニタリングに使用されています。
  • 用途別では、乳がんが2022年の世界市場を独占し、予測期間中もそのリードを維持すると予想されます。開腹外科的生検は、そのような病態の診断において確立された正確性により、疑わしい乳房病変を有する患者を評価するための基準として依然として使用されています。その結果、このセグメントの収益は、乳房病変診断におけるその実証された有効性によって強化されています。
  • 北米は、活動的な組織やがん財団が集中しているため、2022年に最大の収益シェアを占めました。米国の政府組織と民間がん財団の強力なネットワークは、地域の収益創出能力に大きく貢献しています。
  • 主な市場参入企業には、QIAGEN、ANGLE plc、Myriad Genetics、Danaher、F. Hoffmann-La Roche Ltd.、Lucence Diagnostics Pte.Ltd.、GRAIL, Inc.、Guardant Health、BIOCEPT, INC.などです。

目次

第1章 がん生検市場：調査手法と範囲

第2章 がん生検市場：エグゼクティブサマリー

  • 市場の見通し
  • 製品とタイプのスナップショット
  • アプリケーションのスナップショット
  • 競合情勢のスナップショット

第3章 がん生検市場：市場変数、動向、範囲

  • 市場系統の見通し
  • 市場力学
  • 業界分析ツール

第4章 がん生検市場：製品ビジネス分析

  • がん生検市場：製品変動分析
  • 機器
  • キットと消耗品
  • サービス

第5章 がん生検市場：タイプビジネス分析

  • がん生検市場：タイプの変動分析
  • 組織生検
  • リキッドバイオプシー
  • その他

第6章 がん生検市場：用途ビジネス分析

  • がん生検市場：用途変動分析
  • 乳がん
  • 結腸直腸がん
  • 子宮頸がん
  • 肺がん
  • 前立腺がん
  • 皮膚がん
  • 血液がん
  • 腎臓がん
  • 肝臓がん
  • 膵臓がん
  • 卵巣がん
  • その他

第7章 がん生検市場：地域ビジネス分析

  • 地域市場のスナップショット
  • 北米
  • 欧州
  • アジア太平洋地域
  • ラテンアメリカ
  • 中東・アフリカ

第8章 がん生検市場：競合情勢

  • 企業の分類
  • 戦略マッピング
  • 企業の市場シェア分析、2022年
  • 企業プロファイル

第9章 KOLの推奨事項/アナリストの視点

図表

List of Tables

  • Table 1 List of secondary sources
  • Table 2 List of abbreviation
  • Table 3 North America cancer biopsy market, by product, 2018 - 2030 (USD Million)
  • Table 4 North America cancer biopsy market, by type, 2018 - 2030 (USD Million)
  • Table 5 North America cancer biopsy market, by application, 2018 - 2030 (USD Million)
  • Table 6 U.S. cancer biopsy market, by product, 2018 - 2030 (USD Million)
  • Table 7 U.S. cancer biopsy market, by type, 2018 - 2030 (USD Million)
  • Table 8 U.S. cancer biopsy market, by application, 2018 - 2030 (USD Million)
  • Table 9 Canada cancer biopsy market, by product, 2018 - 2030 (USD Million)
  • Table 10 Canada cancer biopsy market, by type, 2018 - 2030 (USD Million)
  • Table 11 Canada cancer biopsy market, by application, 2018 - 2030 (USD Million)
  • Table 12 Europe cancer biopsy market, by product, 2018 - 2030 (USD Million)
  • Table 13 Europe cancer biopsy market, by type, 2018 - 2030 (USD Million)
  • Table 14 Europe cancer biopsy market, by application, 2018 - 2030 (USD Million)
  • Table 15 Germany cancer biopsy market, by product, 2018 - 2030 (USD Million)
  • Table 16 Germany cancer biopsy market, by type, 2018 - 2030 (USD Million)
  • Table 17 Germany cancer biopsy market, by application, 2018 - 2030 (USD Million)
  • Table 18 UK cancer biopsy market, by product, 2018 - 2030 (USD Million)
  • Table 19 UK cancer biopsy market, by type, 2018 - 2030 (USD Million)
  • Table 20 UK cancer biopsy market, by application, 2018 - 2030 (USD Million)
  • Table 21 France cancer biopsy market, by product, 2018 - 2030 (USD Million)
  • Table 22 France cancer biopsy market, by type, 2018 - 2030 (USD Million)
  • Table 23 France cancer biopsy market, by application, 2018 - 2030 (USD Million)
  • Table 24 Spain cancer biopsy market, by product, 2018 - 2030 (USD Million)
  • Table 25 Spain cancer biopsy market, by type, 2018 - 2030 (USD Million)
  • Table 26 Spain cancer biopsy market, by application, 2018 - 2030 (USD Million)
  • Table 27 Italy cancer biopsy market, by product, 2018 - 2030 (USD Million)
  • Table 28 Italy cancer biopsy market, by type, 2018 - 2030 (USD Million)
  • Table 29 Italy cancer biopsy market, by application, 2018 - 2030 (USD Million)
  • Table 30 Denmark cancer biopsy market, by product, 2018 - 2030 (USD Million)
  • Table 31 Denmark cancer biopsy market, by type, 2018 - 2030 (USD Million)
  • Table 32 Denmark cancer biopsy market, by application, 2018 - 2030 (USD Million)
  • Table 33 Sweden cancer biopsy market, by product, 2018 - 2030 (USD Million)
  • Table 34 Sweden cancer biopsy market, by type, 2018 - 2030 (USD Million)
  • Table 35 Sweden cancer biopsy market, by application, 2018 - 2030 (USD Million)
  • Table 36 Norway cancer biopsy market, by product, 2018 - 2030 (USD Million)
  • Table 37 Norway cancer biopsy market, by type, 2018 - 2030 (USD Million)
  • Table 38 Norway cancer biopsy market, by application, 2018 - 2030 (USD Million)
  • Table 39 Asia Pacific cancer biopsy market, by product, 2018 - 2030 (USD Million)
  • Table 40 Asia Pacific cancer biopsy market, by type, 2018 - 2030 (USD Million)
  • Table 41 Asia Pacific cancer biopsy market, by application, 2018 - 2030 (USD Million)
  • Table 42 Japan cancer biopsy market, by product, 2018 - 2030 (USD Million)
  • Table 43 Japan cancer biopsy market, by type, 2018 - 2030 (USD Million)
  • Table 44 Japan cancer biopsy market, by application, 2018 - 2030 (USD Million)
  • Table 45 China cancer biopsy market, by product, 2018 - 2030 (USD Million)
  • Table 46 China cancer biopsy market, by type, 2018 - 2030 (USD Million)
  • Table 47 China cancer biopsy market, by application, 2018 - 2030 (USD Million)
  • Table 48 India cancer biopsy market, by product, 2018 - 2030 (USD Million)
  • Table 49 India cancer biopsy market, by type, 2018 - 2030 (USD Million)
  • Table 50 India cancer biopsy market, by application, 2018 - 2030 (USD Million)
  • Table 51 South Korea cancer biopsy market, by product, 2018 - 2030 (USD Million)
  • Table 52 South Korea cancer biopsy market, by type, 2018 - 2030 (USD Million)
  • Table 53 South Korea cancer biopsy market, by application, 2018 - 2030 (USD Million)
  • Table 54 Thailand cancer biopsy market, by product, 2018 - 2030 (USD Million)
  • Table 55 Thailand cancer biopsy market, by type, 2018 - 2030 (USD Million)
  • Table 56 Thailand cancer biopsy market, by application, 2018 - 2030 (USD Million)
  • Table 57 Australia cancer biopsy market, by product, 2018 - 2030 (USD Million)
  • Table 58 Australia cancer biopsy market, by type, 2018 - 2030 (USD Million)
  • Table 59 Australia cancer biopsy market, by application, 2018 - 2030 (USD Million)
  • Table 60 Latin America cancer biopsy market, by product, 2018 - 2030 (USD Million)
  • Table 61 Latin America cancer biopsy market, by type, 2018 - 2030 (USD Million)
  • Table 62 Latin America cancer biopsy market, by application, 2018 - 2030 (USD Million)
  • Table 63 Brazil cancer biopsy market, by product, 2018 - 2030 (USD Million)
  • Table 64 Brazil cancer biopsy market, by type, 2018 - 2030 (USD Million)
  • Table 65 Brazil cancer biopsy market, by application, 2018 - 2030 (USD Million)
  • Table 66 Mexico cancer biopsy market, by product, 2018 - 2030 (USD Million)
  • Table 67 Mexico cancer biopsy market, by type, 2018 - 2030 (USD Million)
  • Table 68 Mexico cancer biopsy market, by application, 2018 - 2030 (USD Million)
  • Table 69 Argentina cancer biopsy market, by product, 2018 - 2030 (USD Million)
  • Table 70 Argentina cancer biopsy market, by type, 2018 - 2030 (USD Million)
  • Table 71 Argentina cancer biopsy market, by application, 2018 - 2030 (USD Million)
  • Table 72 MEA cancer biopsy market, by product, 2018 - 2030 (USD Million)
  • Table 73 MEA cancer biopsy market, by type, 2018 - 2030 (USD Million)
  • Table 74 MEA cancer biopsy market, by application, 2018 - 2030 (USD Million)
  • Table 75 South Africa cancer biopsy market, by product, 2018 - 2030 (USD Million)
  • Table 76 South Africa cancer biopsy market, by type, 2018 - 2030 (USD Million)
  • Table 77 South Africa cancer biopsy market, by application, 2018 - 2030 (USD Million)
  • Table 78 Saudi Arabia cancer biopsy market, by product, 2018 - 2030 (USD Million)
  • Table 79 Saudi Arabia cancer biopsy market, by type, 2018 - 2030 (USD Million)
  • Table 80 Saudi Arabia cancer biopsy market, by application, 2018 - 2030 (USD Million)
  • Table 81 UAE cancer biopsy market, by product, 2018 - 2030 (USD Million)
  • Table 82 UAE cancer biopsy market, by type, 2018 - 2030 (USD Million)
  • Table 83 UAE cancer biopsy market, by application, 2018 - 2030 (USD Million)
  • Table 84 Kuwait cancer biopsy market, by product, 2018 - 2030 (USD Million)
  • Table 85 Kuwait cancer biopsy market, by type, 2018 - 2030 (USD Million)
  • Table 86 Kuwait cancer biopsy market, by application, 2018 - 2030 (USD Million)

List of Figures

  • Fig. 1 Cancer biopsy market segmentation
  • Fig. 2 Market research process
  • Fig. 3 Information procurement
  • Fig. 4 Primary research pattern
  • Fig. 5 Market research approaches
  • Fig. 6 Value chain-based sizing & forecasting
  • Fig. 7 QFD modeling for market share assessment
  • Fig. 8 Market formulation & validation
  • Fig. 9 Market snapshot
  • Fig. 10 Segment snapshot
  • Fig. 11 Segment snapshot
  • Fig. 12 Competitive landscape
  • Fig. 13 Cancer Biopsy Market Value, 2022 (USD Billion)
  • Fig. 14 Cancer Biopsy - Industry value chain analysis
  • Fig. 15 Cancer biopsy market dynamics
  • Fig. 16 Cancer biopsy market: PORTER's analysis
  • Fig. 17 Cancer biopsy market: PESTEL analysis
  • Fig. 18 Cancer biopsy market: By application: Key takeaways
  • Fig. 19 Cancer biopsy market, by application: Market share, 2022 & 2030
  • Fig. 20 Genetic disorders market, 2018 - 2030 (USD Million)
  • Fig. 21 Oncology market, 2018 - 2030 (USD Million)
  • Fig. 22 Personalized medicine market, 2018 - 2030 (USD Million)
  • Fig. 23 Other application market, 2018 - 2030 (USD Million)
  • Fig. 24 Cancer biopsy market: By product: Key takeaways
  • Fig. 25 Cancer biopsy market, by product: Market share, 2022 & 2030
  • Fig. 26 Instruments market, 2018 - 2030 (USD Million)
  • Fig. 27 Kits and consumables market, 2018 - 2030 (USD Million)
  • Fig. 28 Services market, 2018 - 2030 (USD Million)
  • Fig. 29 Cancer biopsy market: By type: Key takeaways
  • Fig. 30 Cancer biopsy market, by type: Market share, 2022 & 2030
  • Fig. 31 Tissue biopsies market, 2018 - 2030 (USD Million)
  • Fig. 32 Needle biopsies market, 2018 - 2030 (USD Million)
  • Fig. 33 Fine needle aspiration (FNA) market, 2018 - 2030 (USD Million)
  • Fig. 34 Core needle biopsy (CNB) market, 2018 - 2030 (USD Million)
  • Fig. 35 Surgical biopsies market, 2018 - 2030 (USD Million)
  • Fig. 36 Liquid biopsies market, 2018 - 2030 (USD Million)
  • Fig. 37 Others market, 2018 - 2030 (USD Million)
  • Fig. 38 Cancer biopsy market: By application: Key takeaways
  • Fig. 39 Cancer biopsy market, by application: Market share, 2022 & 2030
  • Fig. 40 Breast cancer market, 2018 - 2030 (USD Million)
  • Fig. 41 Colorectal cancer market, 2018 - 2030 (USD Million)
  • Fig. 42 Cervical cancers market, 2018 - 2030 (USD Million)
  • Fig. 43 Lung cancers market, 2018 - 2030 (USD Million)
  • Fig. 44 Prostate cancer market, 2018 - 2030 (USD Million)
  • Fig. 45 Skin cancer market, 2018 - 2030 (USD Million)
  • Fig. 46 Blood cancers market, 2018 - 2030 (USD Million)
  • Fig. 47 Kidney cancers market, 2018 - 2030 (USD Million)
  • Fig. 48 Liver cancer market, 2018 - 2030 (USD Million)
  • Fig. 49 Pancreatic cancers market, 2018 - 2030 (USD Million)
  • Fig. 50 Ovarian cancers market, 2018 - 2030 (USD Million)
  • Fig. 51 Others market, 2018 - 2030 (USD Million)
  • Fig. 52 Cancer biopsy market revenue, by region, 2022 & 2030, (USD Million)
  • Fig. 53 Regional marketplace: Key takeaways
  • Fig. 54 Regional marketplace: Key takeaways
  • Fig. 55 North America: SWOT analysis
  • Fig. 56 North America cancer biopsy market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 57 Key country dynamics
  • Fig. 58 Reimbursement procurement process
  • Fig. 59 U.S. cancer biopsy market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 60 Key country dynamics
  • Fig. 61 Canada cancer biopsy market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 62 Europe: SWOT analysis
  • Fig. 63 Europe cancer biopsy market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 64 Key country dynamics
  • Fig. 65 Germany cancer biopsy market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 66 Key country dynamics
  • Fig. 67 UK cancer biopsy market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 68 Key country dynamics
  • Fig. 69 France color-correcting classes market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 70 Key country dynamics
  • Fig. 71 Italy cancer biopsy market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 72 Key country dynamics
  • Fig. 73 Spain cancer biopsy market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 74 Key country dynamics
  • Fig. 75 Denmark cancer biopsy market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 76 Key country dynamics
  • Fig. 77 Sweden cancer biopsy market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 78 Key country dynamics
  • Fig. 79 Norway cancer biopsy market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 80 Asia Pacific: SWOT analysis
  • Fig. 81 Asia Pacific cancer biopsy market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 82 Key country dynamics
  • Fig. 83 Reimbursement procurement process
  • Fig. 84 Japan cancer biopsy market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 85 Key country dynamics
  • Fig. 86 China cancer biopsy market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 87 Key country dynamics
  • Fig. 88 India cancer biopsy market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 89 Key country dynamics
  • Fig. 90 Australia cancer biopsy market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 91 Key country dynamics
  • Fig. 92 South Korea cancer biopsy market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 93 Key country dynamics
  • Fig. 94 Thailand cancer biopsy market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 95 Latin America: SWOT analysis
  • Fig. 96 Latin America cancer biopsy market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 97 Key country dynamics
  • Fig. 98 Brazil cancer biopsy market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 99 Key country dynamics
  • Fig. 100 Mexico cancer biopsy market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 101 Key country dynamics
  • Fig. 102 Argentina cancer biopsy market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 103 MEA: SWOT analysis
  • Fig. 104 Middle East & Africa cancer biopsy market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 105 Key country dynamics
  • Fig. 106 South Africa cancer biopsy market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 107 Key country dynamics
  • Fig. 108 Saudi Arabia cancer biopsy market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 109 Key country dynamics
  • Fig. 110 UAE cancer biopsy market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 111 Key country dynamics
  • Fig. 112 Kuwait cancer biopsy market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 113 Key company categorization
  • Fig. 114 Company market position analysis
  • Fig. 115 Strategic framework 
目次
Product Code: GVR-4-68039-254-2

Cancer Biopsy Market Growth & Trends:

The global cancer biopsy market size is estimated to reach USD 51.61 billion by 2030, and is projected to expand at a CAGR of 8.04%, according to a new report by Grand View Research, Inc.. The advancement in molecular medicine has facilitated the creation of novel devices for the molecular characterization of cancers. As a result, the rising acceptance and approvals of liquid biopsies are anticipated to be significant driving forces behind the overall market growth.

Numerous emerging manufacturers are dedicated to developing instruments that can improve endoscopy-based cancer biopsies. For instance, in March 2023, BiBBInstruments AB, a Swedish company, established a strong presence in the cancer biopsy instruments market under the brand - EndoDrill. The company changed biopsy instruments that allow rapid and precise diagnosis of cancer patients related to existing biopsy instruments. Moreover, it offers biopsy instruments catering to core needles and flexible endoscopic biopsies. Such companies developing in the market are expected to upsurge the accessibility of cancer biopsy instruments.

The field of oncology-based genomic data analysis and personalized medicine is anticipated to witness lucrative prospects with the emergence of liquid biopsies. Regulatory bodies are actively backing the commercialization of these products and promoting their utilization in clinical settings due to the significant potential they offer. Liquid biopsy facilitates cancer detection through various body fluids, and the advancements in this technique have made it an appealing noninvasive approach for obtaining cancer biomaterials for diagnostic purposes.

The liquid biopsies segment is projected to experience rapid expansion in the upcoming years, driven by significant investments and strategic efforts from companies engaged in biopharmaceutical manufacturing and genomic data analysis. Emerging companies are showing a strong inclination towards forming partnerships with established industry participants like QIAGEN Bioinformatics, Fabric Genomics, Agilent Technologies, and SOPHiA Genetics. This collaborative trend is expected to further boost the overall market growth.

Cancer Biopsy Market Report Highlights:

  • In 2022, kits and consumables held the largest market share by product, and this dominance is projected to persist throughout the forecast period. The increased adoption of kits and consumables can be attributed to the notable shift from tumor biopsies to liquid biopsies
  • Tissue biopsies remain a fundamental aspect of the biopsy process and are widely utilized across various diagnostic applications. Furthermore, tumor biopsies are primarily employed for individual-level diagnosis and monitoring the efficacy of ongoing oncology treatments
  • In terms of application, breast cancer dominated the global market in 2022 and is expected to maintain its lead throughout the forecast period. Open surgical biopsy remains a reference standard for evaluating patients with suspicious breast lesions, owing to its established accuracy in diagnosing such conditions. Consequently, this segment's revenue is bolstered by its proven efficacy in breast lesion diagnosis
  • North America held the largest revenue share in 2022 owing to the concentrated pool of active organizations and cancer foundations. The strong network of government organizations and private cancer foundations in the U.S. has made significant contributions to the regional revenue generation capacity
  • Some of the key market participants are QIAGEN, ANGLE plc, Myriad Genetics, Danaher, F. Hoffmann-La Roche Ltd., Lucence Diagnostics Pte. Ltd., GRAIL, Inc., Guardant Health, and BIOCEPT, INC. among others

Table of Contents

Chapter 1 Cancer Biopsy Market: Research Methodology And Scope

  • 1.1 Market Segmentation and Scope
    • 1.1.1 Segment Definitions
      • 1.1.1.1 Product Segment
      • 1.1.1.2 Type Segment
      • 1.1.1.3 Application Segment
      • 1.1.1.4 End Use Segment
  • 1.2 Regional Scope
  • 1.3 Estimates And Forecast Timeline
  • 1.4 Objectives
    • 1.4.1 Objective - 1
    • 1.4.2 Objective - 2
    • 1.4.3 Objective - 3
  • 1.5 Research Methodology
  • 1.6 Information Procurement
    • 1.6.1 Purchased Database
    • 1.6.2 Gvr's Internal Database
    • 1.6.3 Secondary Sources
    • 1.6.4 Primary Research
  • 1.7 Information Or Data Analysis
    • 1.7.1 Data Analysis Models
  • 1.8 Market Formulation & Validation
  • 1.9 Model Details
    • 1.9.1 Commodity Flow Analysis
  • 1.10 List Of Secondary Sources
  • 1.11 List Of Abbreviations

Chapter 2 Cancer Biopsy Market: Executive Summary

  • 2.1 Market Outlook
  • 2.2 Product And Type Snapshot
  • 2.3 Application Snapshot
  • 2.4 Competitive Landscape Snapshot

Chapter 3 Cancer Biopsy Market: Market Variables, Trends & Scope

  • 3.1 Market Lineage Outlook
    • 3.1.1 Related/Ancillary Market Outlook
  • 3.2 Market Dynamics
    • 3.2.1 Market Drivers Analysis
      • 3.2.1.1 Advent Of Liquid Biopsy
      • 3.2.1.2 Transition Of Novel Oncology Diagnostics From Bench To Clinics
      • 3.2.1.3 Advancements In Quality And Payment Pertaining To Genetic Cancer Tests
    • 3.2.2 Market Restraint Analysis
      • 3.2.2.1 Risks Associated With Biopsy Procedures
      • 3.2.2.2 Technical And Clinical Challenges
  • 3.3 Industry Analysis Tools
    • 3.3.1 Porter's Analysis
    • 3.3.2 Pestel Analysis

Chapter 4 Cancer Biopsy Market: Product Business Analysis

  • 4.1 Cancer Biopsy Market: Product Movement Analysis
  • 4.2 Instruments
    • 4.2.1 Instruments Market Estimates And Forecast, 2018 - 2030 (USD Million)
  • 4.3 Kits And Consumabkes
    • 4.3.1 Kits And Consumabels Market Estimates And Forecast, 2018 - 2030 (USD Million)
  • 4.4 Services
    • 4.4.1 Services Market Estimates And Forecast, 2018 - 2030 (USD Million)

Chapter 5 Cancer Biopsy Market: Type Business Analysis

  • 5.1 Cancer Biopsy Market: Type Movement Analysis
  • 5.2 Tissue Biopsies
    • 5.2.1 Tissue Biopsies Market Estimates And Forecast, 2018 - 2030 (USD Million)
    • 5.2.2 Needle Biopsies
      • 5.2.2.1 Needle Biopsies Market Estimates And Forecast, 2018 - 2030 (USD Million)
      • 5.2.2.2 Fine Needle Aspiration (Fna)
      • 5.2.2.2.1 Fine Needle Aspiration (Fna) Market Estimates And Forecast, 2018 - 2030 (USD Million)
      • 5.2.2.3 Core Needle Biopsy (Cnb)
      • 5.2.2.3.1 Core Needle Biopsy (Cnb) Market Estimates And Forecast, 2018 - 2030 (USD Million)
    • 5.2.3 Surgical Biopsies
      • 5.2.3.1 Surgical Biopsies Market Estimates And Forecast, 2018 - 2030 (USD Million)
  • 5.3 Liquid Biopsies
    • 5.3.1 Liquid Biopsies Market Estimates And Forecast, 2018 - 2030 (USD Million)
  • 5.4 Others
    • 5.4.1 Others Market Estimates And Forecast, 2018 - 2030 (USD Million)

Chapter 6 Cancer Biopsy Market: Application Business Analysis

  • 6.1 Cancer Biopsy Market: Application Movement Analysis
  • 6.2 Breast Cancer
    • 6.2.1 Breast Cancer Market Estimates And Forecast, 2018 - 2030 (USD Million)
  • 6.3 Colorectal Cancer
    • 6.3.1 Colorectal Cancer Market Estimates And Forecast, 2018 - 2030 (USD Million)
  • 6.4 Cervical Cancers
    • 6.4.1 Cervical Cancers Market Estimates And Forecast, 2018 - 2030 (USD Million)
  • 6.5 Lung Cancers
    • 6.5.1 Lung Cancers Market Estimates And Forecast, 2018 - 2030 (USD Million)
  • 6.6 Prostate Cancers
    • 6.6.1 Prostate Cancers Market Estimates And Forecast, 2018 - 2030 (USD Million)
  • 6.7 Skin Cancers
    • 6.7.1 Skin Cancers Market Estimates And Forecast, 2018 - 2030 (USD Million)
  • 6.8 Blood Cancers
    • 6.8.1 Blood Cancers Market Estimates And Forecast, 2018 - 2030 (USD Million)
  • 6.9 Kidney Cancers
    • 6.9.1 Kidney Cancers Market Estimates And Forecast, 2018 - 2030 (USD Million)
  • 6.10 Liver Cancers
    • 6.10.1 Liver Cancers Market Estimates And Forecast, 2018 - 2030 (USD Million)
  • 6.11 Pancreatic Cancers
    • 6.11.1 Pancreatic Cancers Market Estimates And Forecast, 2018 - 2030 (USD Million)
  • 6.12 Ovarian Cancers
    • 6.12.1 Ovarian Cancers Market Estimates And Forecast, 2018 - 2030 (USD Million)
  • 6.13 Others
    • 6.13.1 Others Market Estimates And Forecast, 2018 - 2030 (USD Million)

Chapter 7 Cancer Biopsy Market: Regional Business Analysis

  • 7.1 Regional Market Snapshot
  • 7.2 North America
    • 7.2.1 North America Cancer Biopsy Market Estimates And Forecast, 2018 - 2030 (USD Million)
    • 7.2.2 U.S.
      • 7.2.2.1 U.S. Cancer Biopsy Market, 2018 - 2030 (USD Million)
      • 7.2.2.2 Key Country Dynamics
      • 7.2.2.3 Regulatory Framework
      • 7.2.2.4 Reimbursement Scenario
    • 7.2.3 Canada
      • 7.2.3.1 Canada Cancer Biopsy Market, 2018 - 2030 (USD Million)
      • 7.2.3.2 Key Country Dynamics
      • 7.2.3.3 Regulatory Framework
      • 7.2.3.4 Reimbursement Scenario
  • 7.3 Europe
    • 7.3.1 Europe Cancer Biopsy Market, 2018 - 2030 (USD Million)
    • 7.3.2 Uk
      • 7.3.2.1 Uk Cancer Biopsy Market, 2018 - 2030 (USD Million)
      • 7.3.2.2 Key Country Dynamics
      • 7.3.2.3 Regulatory Framework
      • 7.3.2.4 Reimbursement Scenario
    • 7.3.3 Germany
      • 7.3.3.1 Germany Cancer Biopsy Market, 2018 - 2030 (USD Million)
      • 7.3.3.2 Key Country Dynamics
      • 7.3.3.3 Regulatory Framework
      • 7.3.3.4 Reimbursement Scenario
    • 7.3.4 Spain
      • 7.3.4.1 Spain Cancer Biopsy Market, 2018 - 2030 (USD Million)
      • 7.3.4.2 Key Country Dynamics
      • 7.3.4.3 Regulatory Framework
      • 7.3.4.4 Reimbursement Scenario
    • 7.3.5 France
      • 7.3.5.1 France Cancer Biopsy Market, 2018 - 2030 (USD Million)
      • 7.3.5.2 Key Country Dynamics
      • 7.3.5.3 Regulatory Framework
      • 7.3.5.4 Reimbursement Scenario
    • 7.3.6 Italy
      • 7.3.6.1 Italy Cancer Biopsy Market, 2018 - 2030 (USD Million)
      • 7.3.6.2 Key Country Dynamics
      • 7.3.6.3 Regulatory Framework
      • 7.3.6.4 Reimbursement Scenario
    • 7.3.7 Denmark
      • 7.3.7.1 Denmark Cancer Biopsy Market, 2018 - 2030 (USD Million)
      • 7.3.7.2 Key Country Dynamics
      • 7.3.7.3 Regulatory Framework
      • 7.3.7.4 Reimbursement Scenario
    • 7.3.8 Sweden
      • 7.3.8.1 Sweden Cancer Biopsy Market, 2018 - 2030 (USD Million)
      • 7.3.8.2 Key Country Dynamics
      • 7.3.8.3 Regulatory Framework
      • 7.3.8.4 Reimbursement Scenario
    • 7.3.9 Norway
      • 7.3.9.1 Norway Cancer Biopsy Market, 2018 - 2030 (USD Million)
      • 7.3.9.2 Key Country Dynamics
      • 7.3.9.3 Regulatory Framework
      • 7.3.9.4 Reimbursement Scenario
  • 7.4 Asia Pacific
    • 7.4.1 Asia-Pacific Cancer Biopsy Market, 2018 - 2030 (USD Million)
    • 7.4.2 Japan
      • 7.4.2.1 Japan Cancer Biopsy Market, 2018 - 2030 (USD Million)
      • 7.4.2.2 Key Country Dynamics
      • 7.4.2.3 Regulatory Framework
      • 7.4.2.4 Reimbursement Scenario
    • 7.4.3 China
      • 7.4.3.1 China Cancer Biopsy Market, 2018 - 2030 (USD Million)
      • 7.4.3.2 Key Country Dynamics
      • 7.4.3.3 Regulatory Framework
      • 7.4.3.4 Reimbursement Scenario
    • 7.4.4 India
      • 7.4.4.1 India Cancer Biopsy Market, 2018 - 2030 (USD Million)
      • 7.4.4.2 Key Country Dynamics
      • 7.4.4.3 Regulatory Framework
      • 7.4.4.4 Reimbursement Scenario
    • 7.4.5 South Korea
      • 7.4.5.1 South Korea Cancer Biopsy Market, 2018 - 2030 (USD Million)
      • 7.4.5.2 Key Country Dynamics
      • 7.4.5.3 Regulatory Framework
      • 7.4.5.4 Reimbursement Scenario
    • 7.4.6 Thailand
      • 7.4.6.1 Thailand Cancer Biopsy Market, 2018 - 2030 (USD Million)
      • 7.4.6.2 Key Country Dynamics
      • 7.4.6.3 Regulatory Framework
      • 7.4.6.4 Reimbursement Scenario
    • 7.4.7 Australia
      • 7.4.7.1 Australia Cancer Biopsy Market, 2018 - 2030 (USD Million)
      • 7.4.7.2 Key Country Dynamics
      • 7.4.7.3 Regulatory Framework
      • 7.4.7.4 Reimbursement Scenario
  • 7.5 Latin America
    • 7.5.1 Latin America Cancer Biopsy Market, 2018 - 2030 (USD Million)
    • 7.5.2 Brazil
      • 7.5.2.1 Brazil Cancer Biopsy Market, 2018 - 2030 (USD Million)
      • 7.5.2.2 Key Country Dynamics
      • 7.5.2.3 Regulatory Framework
      • 7.5.2.4 Reimbursement Scenario
    • 7.5.3 Mexico
      • 7.5.3.1 Mexico Cancer Biopsy Market, 2018 - 2030 (USD Million)
      • 7.5.3.2 Key Country Dynamics
      • 7.5.3.3 Regulatory Framework
      • 7.5.2.4 Reimbursement Scenario
    • 7.5.4 Argentina
      • 7.5.4.1 Argentina Cancer Biopsy Market, 2018 - 2030 (USD Million)
      • 7.5.4.2 Key Country Dynamics
      • 7.5.4.3 Regulatory Framework
      • 7.5.4.4 Reimbursement Scenario
  • 7.6 MEA
    • 7.6.1 MEA Cancer Biopsy Market, 2018 - 2030 (USD Million)
    • 7.6.2 South Africa
      • 7.6.2.1 South Africa Cancer Biopsy Market, 2018 - 2030 (USD Million)
      • 7.6.2.2 Key Country Dynamics
      • 7.6.2.3 Regulatory Framework
      • 7.6.2.4 Reimbursement Scenario
    • 7.6.3 Saudi Arabia
      • 7.6.3.1 Saudi Arabia Cancer Biopsy Market, 2018 - 2030 (USD Million)
      • 7.6.3.2 Key Country Dynamics
      • 7.6.3.3 Regulatory Framework
      • 7.6.3.4 Reimbursement Scenario
    • 7.6.4 Uae
      • 7.6.4.1 Uae Cancer Biopsy Market, 2018 - 2030 (USD Million)
      • 7.6.4.2 Key Country Dynamics
      • 7.6.4.3 Regulatory Framework
      • 7.6.2.4 Reimbursement Scenario
    • 7.6.5 Kuwait
      • 7.6.5.1 Kuwait Cancer Biopsy Market, 2018 - 2030 (USD MILLION)
      • 7.6.5.2 Key Country Dynamics
      • 7.6.5.3 Regulatory Framework
      • 7.6.5.4 Reimbursement Scenario

Chapter 8 Cancer Biopsy Market: Competitive Landscape

  • 8.1 Company Categorization
  • 8.2 Strategy Mapping
    • 8.2.1 New product launch
    • 8.2.2 Partnerships
    • 8.2.3 Acquisition
    • 8.2.4 Collaboration
    • 8.2.5 Funding
  • 8.3 Company Market Share Analysis, 2022
  • 8.4 Company Profiles
    • 8.4.1 QIAGEN
      • 8.4.1.1 Company overview
      • 8.4.1.2 Financial performance
      • 8.4.1.3 Product benchmarking
      • 8.4.1.4 Strategic initiatives
    • 8.4.2 ILLUMINA, INC.
      • 8.4.2.1 Company overview
      • 8.4.2.2 Financial performance
      • 8.4.2.3 Product benchmarking
      • 8.4.2.4 Strategic initiatives
    • 8.4.3 ANGLE PLC
      • 8.4.3.1 Company overview
      • 8.4.3.2 Financial performance
      • 8.4.3.3 Product benchmarking
      • 8.4.3.4 Strategic initiatives
    • 8.4.4 BD (BECTON, DICKINSON AND COMPANY)
      • 8.4.4.1 Company overview
      • 8.4.4.2 Financial performance
      • 8.4.4.3 Product benchmarking
      • 8.4.4.4 Strategic initiatives
    • 8.4.5 MYRIAD GENETICS
      • 8.4.5.1 Company overview
      • 8.4.5.1.1 Counsyl, Inc.
      • 8.4.5.2 Financial performance
      • 8.4.5.3 Product benchmarking
      • 8.4.5.4 Strategic initiatives
    • 8.4.6 HOLOGIC, INC.
      • 8.4.6.1 Company overview
      • 8.4.6.2 Financial performance
      • 8.4.6.3 Product benchmarking
    • 8.4.7 BIOCEPT, INC.
      • 8.4.7.1 Company overview
      • 8.4.7.2 Financial performance
      • 8.4.7.3 Product benchmarking
      • 8.4.7.4 Strategic initiatives
    • 8.4.8 THERMO FISHER SCIENTIFIC, INC.
      • 8.4.8.1 Company overview
      • 8.4.8.2 Financial performance
      • 8.4.8.3 Product benchmarking
      • 8.4.8.4 Strategic initiatives
    • 9.4.9 DANAHER
      • 8.4.9.1 Company overview
      • 8.4.9.2 Beckman Coulter, Inc
      • 8.4.9.3 Radiometer Medical ApS
      • 8.4.9.4 HemoCue AB
      • 8.4.9.5 Financial performance
      • 8.4.9.6 Product benchmarking
    • 8.4.10 F. HOFFMANN-LA ROCHE LTD.
      • 8.4.10.1 Company overview
      • 8.4.10.2 FOUNDATION MEDICINE, INC.
      • 8.4.10.3 Financial performance
      • 8.4.10.4 Product benchmarking
    • 8.4.11 LUCENCE DIAGNOSTICS PTE. LTD.
      • 8.4.11.1 Company overview
      • 8.4.11.2 Financial performance
      • 8.4.11.3 Product benchmarking
      • 8.4.11.4 Strategic initiatives
    • 8.4.12 GRAIL, INC.
      • 8.4.12.1 Company overview
      • 8.4.12.2 Financial performance
      • 8.4.12.3 Product benchmarking
      • 8.4.12.4 Strategic initiatives
    • 8.4.13 GUARDANT HEALTH
      • 8.4.13.1 Company overview
      • 8.4.13.2 Financial performance
      • 8.4.13.3 Product benchmarking
      • 8.4.13.4 Strategic initiatives
    • 8.4.14 EXACT SCIENCES CORPORATION
      • 8.4.14.1 Company overview
      • 8.4.14.2 Financial performance
      • 8.4.14.3 Product benchmarking
      • 8.4.14.4 Strategic initiatives
    • 8.4.15 FREENOME HOLDINGS, INC.
      • 8.4.15.1 Company overview
      • 8.4.15.2 Financial performance
      • 8.4.15.3 Product benchmarking
      • 8.4.15.4 Strategic initiatives
    • 8.4.16 BIODESIX (INTEGRATED DIAGNOSTICS)
      • 8.4.16.1 Company overview
      • 8.4.16.2 Financial performance
      • 8.4.16.3 Product benchmarking
      • 8.4.16.4 Strategic initiatives
    • 8.4.17 ONCIMMUNE
      • 8.4.17.1 Company overview
      • 8.4.17.2 Financial performance
      • 8.4.17.3 Product benchmarking
      • 8.4.17.4 Strategic initiatives
    • 8.4.18 EPIGENOMICS AG.
      • 8.4.18.1 Company overview
      • 8.4.18.2 Financial performance
      • 8.4.18.3 Product benchmarking
      • 8.4.18.4 Strategic initiatives
    • 8.4.19 HELIOHEALTH (LABORATORY FOR ADVANCED MEDICINE)
      • 8.4.19.1 Company overview
      • 8.4.19.2 Financial performance
      • 8.4.19.3 Product benchmarking
      • 8.4.19.4 Strategic initiatives
    • 8.4.20 GENESYSTEMS, INC. (GENESYS BIOLABS)
      • 8.4.20.1 Company overview
      • 8.4.20.2 Financial performance
      • 8.4.20.3 Product benchmarking
      • 8.4.20.4 Strategic initiatives
    • 8.4.21 CHRONIX BIOMEDICAL, INC.
      • 8.4.21.1 Company overview
      • 8.4.21.2 Financial performance
      • 8.4.21.3 Product benchmarking
      • 8.4.21.4 Strategic initiatives
    • 8.4.22 PERSONAL GENOME DIAGNOSTICS INC.
      • 8.4.22.1 Company overview
      • 8.4.22.2 Financial performance
      • 8.4.22.3 Product benchmarking
      • 8.4.22.4 Strategic initiatives
    • 8.4.23 NATERA, INC.
      • 8.4.23.1 Company overview
      • 8.4.23.2 Financial performance
      • 8.4.23.3 Product benchmarking
      • 8.4.23.4 Strategic initiatives
    • 8.4.24 PERSONALIS INC.
      • 8.4.16.1 Company overview
      • 8.4.24.2 Financial performance
      • 8.4.24.3 Product benchmarking
      • 8.4.24.4 Strategic initiatives

Chapter 9 KOL Recommendations/Analyst Perspective